Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.

Nature - 14 Feb 2013

Das Thakur Meghna, Salangsang Fernando, Landman Allison S, Sellers William R, Pryer Nancy K, Levesque Mitchell P, Dummer Reinhard, McMahon Martin, Stuart Darrin D

Abstract excerpt

Mutational activation of BRAF is the most prevalent genetic alteration in human melanoma, with ≥50% of tumours expressing the BRAF(V600E) oncoprotein. Moreover, the marked tumour regression and improved survival of late-stage BRAF-mutated melanoma patients in response to treatment with vemurafenib demonstrates the essential role of oncogenic BRAF in melanoma maintenance. However, as most patients relapse with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Administration Schedule
Share to Extracellular Signal-Regulated MAP Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Mitogen-Activated Protein Kinase Kinases

Share to Neoplasm Transplantation

Share to Sulfonamides

Share to Vemurafenib

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 23302800
DOI: 10.1038/nature11814
PMCID: PMC3930354

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.PMID 23302800Read ↗

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.Semantic proximity Read ↗

Vemurafenib: the road to personalized medicine in melanoma.Semantic proximity Read ↗

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.Semantic proximity Read ↗

Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.Semantic proximity Read ↗

Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.Semantic proximity Read ↗

Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanomaSemantic proximity Read ↗

Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy ResistanceSemantic proximity Read ↗

Understanding the potential benefits of adaptive therapy for metastatic melanomaSemantic proximity Read ↗

Dissecting targeted therapy resistance: Integrating models to quantify environment mediated drug resistanceSemantic proximity Read ↗

Intermittent treatment of BRAFV600E melanoma cells delays resistance by adaptive resensitization to drug rechallenge.Semantic proximity Read ↗

The development of drug resistance in metastatic tumours under chemotherapy: An evolutionary perspective.Semantic proximity Read ↗

Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.